Needham analyst Ami Fadia has maintained their neutral stance on MRUS stock, giving a Hold rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ami Fadia’s rating is based on the current data surrounding Merus’s petosemtamab treatment in colorectal cancer, which does not yet provide compelling evidence of strong clinical activity. The abstract data presented at the Triple meeting showed mixed results across different lines of treatment.
In the first-line treatment, although the combination with FOLFOX/FOLFIRI showed a high response rate, the sample size was too small to draw definitive conclusions. The second-line treatment results were slightly better than previous benchmarks, but again, the data is not mature enough to confirm these findings. Lastly, the monotherapy in the third-line treatment showed limited efficacy, indicating that more follow-up is necessary. These factors contribute to the Hold rating as further data is needed to assess the true potential of petosemtamab in colorectal cancer.
According to TipRanks, Fadia is a 5-star analyst with an average return of 11.8% and a 50.11% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Immuneering, Biogen, and Jazz Pharmaceuticals.